Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
For the full year, revenue was USD 330.53 million compared to USD 108.46 million a year ago. Net loss was USD 145.22 million compared to USD 325.99 million a year ago. Basic loss per share from continuing operations was USD 1.06 compared to USD 2.6 a year ago.